Chronic aspergillosis treatment market
Chronic Aspergillosis Treatment Market, by Drug Class (Corticosteroids and Anti-fungal Drugs), by Disease Type (Simple Aspergilloma, Chronic Cavitary Pulmonary Aspergillosis, Chronic Fibrosing Pulmonary Aspergillosis, Subacute Invasive Aspergillosis, Allergic Bronchopulmonary Aspergillosis [ABPA], and Severe Asthma With Fungal Sensitization [SAFS]), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies and Drug Store, and E-commerce), and by Region (North America, Latin America, Europe, Asia-Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2021 - 2028
- Sep 2021
- CMI4611
- 204 Pages
- Excel & Pdf
- Pharmaceutical
Chronic pulmonary aspergillosis (CPA) is a serious long-term fungal disease of the lung with a worldwide prevalence. Chronic pulmonary aspergillosis (CPA) complicates conditions including tuberculosis, chronic obstructive pulmonary disease and sarcoidosis, and is associated with high morbidity and mortality. Chronic pulmonary aspergillosis (CPA) is characterized by slowly progressive destruction of lung parenchyma, in the form of single of multiple cavities, nodules, infiltrates or fibrosis, with or without an aspergilloma.
The global chronic aspergillosis treatment market is estimated to be valued at US$ 2,916.3 million in 2021 and is expected to exhibit a CAGR of 4.8 % during the forecast period (2021-2028).
Figure 1.Global Chronic Aspergillosis Treatment Market Share (%) in Terms of Value, By Drug Class, 2021
Increasing incidence and prevalence of aspergillosis is expected to drive the market growth during the forecast period.
Increasing prevalence of aspergillosis is expected to drive the global chronic aspergillosis treatment market growth over the forecast period. For instance, according to the National Organization for Rare Disorders, aspergillosis has been reported from all over the world in recent years. Allergic bronchopulmonary aspergillosis has been estimated to affect about one to four million people worldwide annually. Moreover, according to the same source, chronic pulmonary aspergillosis is estimated to affect about three million people worldwide every year.
Chronic Aspergillosis Treatment Market Report Coverage
Report Coverage | Details | ||
---|---|---|---|
Base Year: | 2020 | Market Size in 2021: | US$ 2,916.3 Mn |
Historical Data for: | 2017 to 2020 | Forecast Period: | 2021 to 2028 |
Forecast Period 2021 to 2028 CAGR: | 4.8% | 2028 Value Projection: | US$ 4,056.4 Mn |
Geographies covered: |
|
||
Segments covered: |
|
||
Companies covered: |
Astellas Pharma Inc., Abbott Laboratories, Pfizer Inc., Pulmocide Ltd., Johnson & Johnson, Mylan N.V., Glenmark Pharmaceuticals, Merck & Co., Inc., Mayne Pharma Group Limited, GlaxoSmithKline plc., PULMATRiX, Inc., F2G Ltd, Teva Pharmaceutical Industries Ltd., and Novartis International AG |
||
Growth Drivers: |
|
||
Restraints & Challenges: |
|
Figure 2.Global Chronic Aspergillosis Treatment Market Share (%), By Disease Type, 2021
Robust product pipeline of chronic aspergillosis is expected to drive the market growth during the forecast period.
Robust product pipeline for the treatment of chronic aspergillosis which are expected to launch during the forecast period is anticipated to drive the growth of the global chronic aspergillosis treatment market. For instance, on September 15, 2020, Regeneron Pharmaceuticals, a biopharmaceutical company, initiated phase III, a randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of dupilumab in patients with allergic bronchopulmonary aspergillosis. The study is estimated to be completed by October 23, 2023.
Global Chronic Aspergillosis Treatment Market– Impact of Coronavirus (COVID-19) Pandemic
According to Centers for Disease Control and Prevention, investigators in Spain and the U.S. added 20 new case reports to mounting evidence that patients with coronavirus disease 2019 (COVID-19) are at risk of developing pulmonary aspergillosis. The coronavirus (COVID 19) pandemic and lockdown in various countries across the globe have impacted the financial status of businesses in all sectors. Private healthcare sector is one of the sectors, which is majorly impacted by the COVID-19 pandemic. Moreover, coronavirus pandemic has negatively impacted the development, production, and supply of pharmaceutical products and affected growth of the medication used in treatment of chronic aspergillosis such as antifungal drugs and corticosteroids manufactured by various companies across the regions such as North America, Europe, and Asia Pacific. The supply and production of pharmaceutical products is also affected due to COVID-19 pandemic lockdown imposed globally. This lockdown has resulted in closure of industrial establishments, except manufacturing of essential commodities, and disruption in supply chain of the pharmaceutical products. Thus, COVID-19 pandemic has affected the economy in three main ways; 1) By directly affecting the production and demand; 2) By creating disruptions in distribution channels; and 3) By its financial impact on firms and financial markets. Thus, the impact of coronavirus (COVID-19) pandemic is expected to limit growth of the global chronic aspergillosis treatment market during the forecast period
Global Chronic Aspergillosis Treatment Market: Restraint
The major factors that are expected to hinder growth of the global chronic aspergillosis treatment market include increasing generic competition and complications associated with drugs used in the treatment of chronic aspergillosis. For instance, in November 2016, Ajanta Pharma, a pharmaceutical company, launched voriconazole tablets in 50-mg and 200-mg doses in the U.S. market. These tablets are the equivalent generic version of Vfend, an antifungal drug from Pfizer. Vfend is used to treat conditions such as invasive aspergillosis, candidemia, and serious infections caused by Scedosporium apiospermum and Fusarium species.
Key Players
Major players operating in the global chronic aspergillosis treatment market include Astellas Pharma Inc., Abbott Laboratories, Pfizer Inc., Pulmocide Ltd., Johnson & Johnson, Mylan N.V., Glenmark Pharmaceuticals, Merck & Co., Inc., Mayne Pharma Group Limited, GlaxoSmithKline plc., PULMATRiX, Inc., F2G Ltd, Teva Pharmaceutical Industries Ltd., and Novartis International AG
Table of Contents
- Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
- Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snapshot, By Drug Class
- Market Snapshot, By Disease Type
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
- Coherent Opportunity Map (COM)
- Report Description
- Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Opportunity
- Impact Analysis
- Key Developments
- Market Trends
- Epidemiology
- Incidence rate of Chronic Aspergillosis (Asthma, COPD, Bronchiectasis, and others)
- Product Approvals/Launches
- Pipeline Analysis
- Regulatory Scenario
- PEST Analysis
- Merger, Acquisition & Agreements
- Treatment Algorithm
- Market Dynamics
- Global Chronic Aspergillosis Treatment Market– Impact of Coronavirus (COVID-19) Pandemic
- Supply and Demand Analysis
- COVID-19 Impact on Clinical Trials
- Economic Impact
- Global Chronic Aspergillosis Treatment Market, By Drug Class, 2017 – 2028, (US$ Mn)
- Introduction
- Market Share Analysis, 2021 and 2028 (%)
- Y-o-Y Growth Analysis, 2017 – 2028
- Segment Trends
- Corticosteroids
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
- Anti-fungal Drugs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
- Introduction
- Global Chronic Aspergillosis Treatment Market, By Disease Type, 2017 – 2028, (US$ Mn)
- Introduction
- Market Share Analysis, 2021 and 2028 (%)
- Y-o-Y Growth Analysis, 2017 – 2028
- Segment Trends
- Simple Aspergilloma
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Million)
- Chronic Cavitary Pulmonary Aspergillosis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Million)
- Chronic Fibrosing Pulmonary Aspergillosis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Million)
- Subacute Invasive Aspergillosis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Million)
- Allergic Bronchopulmonary Aspergillosis [ABPA]
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Million)
- Severe Asthma With Fungal Sensitization [SAFS]
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Million)
- Introduction
- Global Chronic Aspergillosis Treatment Market, By Distribution Channel, 2017 – 2028, (US$ Mn)
- Introduction
- Market Share Analysis, 2021 and 2028 (%)
- Y-o-Y Growth Analysis, 2017 – 2028
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Million)
- Retail Pharmacies and Drug Store
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Million)
- E-commerce
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Million)
- Hospital Pharmacies
- Introduction
- Global Chronic Aspergillosis Treatment Market, By Region, 2017 – 2028, (US$ Mn)
- Introduction
- Market Share Analysis, By Region, 2021 and 2028 (%)
- Y-o-Y Growth Analysis, For Regions, 2017–2028
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 – 2028, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2017 – 2028, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 – 2028, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Countries, 2017 – 2028, (US$ Mn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 – 2028, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2017 – 2028, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 – 2028, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Countries, 2017 – 2028, (US$ Mn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 – 2028, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2017 – 2028, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 – 2028, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Countries, 2017 – 2028, (US$ Mn)
- U.K.
- Germany
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 – 2028, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2017 – 2028, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 – 2028, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Countries, 2017 – 2028, (US$ Mn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 – 2028, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2017 – 2028, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 – 2028, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Countries, 2017 – 2028, (US$ Mn)
- GCC
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 – 2028, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2017 – 2028, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 – 2028, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Region/Countries, 2017 – 2028, (US$ Mn)
- North Africa
- Central Africa
- South Africa
- Introduction
- Competitive Landscape
- Heat Map Analysis
- Market Share Analysis
- Astellas Pharma Inc.*
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Abbott Laboratories
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Pfizer Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Pulmocide Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Johnson & Johnson
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Mylan N.V.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Glenmark Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Merck & Co., Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Mayne Pharma Group Limited
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- GlaxoSmithKline plc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- PULMATRiX, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- F2G Ltd
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Teva Pharmaceutical Industries Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Novartis International AG
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Astellas Pharma Inc.*
- Analyst Views
- Section
- Research Methodology
- About us
*Browse 35 market data tables and 33 figures on "Chronic Aspergillosis Treatment Market” - Global forecast to 2028